News Quantified

SVRA – savara, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Savara Announces New Employment Inducement Grant

Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences [Yahoo! Finance]

Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences

Savara Inc (NASDAQ: SVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.

Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

4.9%

MISS

-9.7%

IN-LINE

1.0%

MISS

1.0%

MISS

Form 4 Savara Inc For: Mar 31 Filed by: RAMSAY DAVID A

Form 8-K Savara Inc For: Mar 31

Form SCHEDULE 13D/A Savara Inc Filed by: Bain Capital Life Sciences Fund II, L.P.

Form 10-K Savara Inc For: Dec 31

Form 8-K Savara Inc For: Mar 26

Top News Gainers

12/30 Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) 180.6%

11/15 Form 8-K Savara Inc For: Nov 15 21.1%

11/27 Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 18.9%

12/20 Form 8-K Savara Inc For: Dec 20 15.1%

6/28 Form 4 Savara Inc For: Jun 26 Filed by: RAMSAY DAVID A 13.9%

12/20 Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million 10.4%

3/25 Statement Of Support By The PAP Foundation, Inc. For FDA Approval Of GM-CSF Treatment For aPAP 8.2%

10/31 Savara to Report Third Quarter 2019 Financial Results and Provide Business Update 7.3%

3/17 Savara Inc (NASDAQ: SVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. 6.3%

4/9 Form SC 13G/A Savara Inc Filed by: BlackRock Inc. 6.1%

Top News Decliners

10/2 Savara Announces FDA Response From Type C Meeting on Molgradex for aPAP Development Program -58.5%

3/17 Form 4 Savara Inc For: Mar 10 Filed by: Sun Ricky -19.4%

2/3 Form 8-K Savara Inc For: Jan 31 -15.8%

4/2 Form 8-K Savara Inc For: Mar 31 -14.3%

12/30 Form SC 13D Savara Inc Filed by: Bain Capital Life Sciences Fund II, L.P. -12.8%

3/12 Q4/2019 12/31/2019 EPS -0.720 ZacksConsensus -0.310 ActVsEst (0.410) - Miss -9.8%

3/30 Savara Provides Business Update in Response to COVID-19 Pandemic -9.8%

12/3 Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors -8.4%

8/8 Q2/2019 6/30/2019 EPS -0.570 ZacksConsensus -0.430 ActVsEst (0.140) - Miss -8.4%

6/13 Savara Inc (NASDAQ: SVRA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -8.2%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day